A5031780257- Protease and Inhibitor Mechanisms
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Cell Adhesion Molecules Research
- Colorectal Cancer Treatments and Studies
- Genomics and Chromatin Dynamics
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Galectins and Cancer Biology
- Lung Cancer Research Studies
- Colorectal Cancer Screening and Detection
- Advanced Biosensing Techniques and Applications
- Gene expression and cancer classification
- Blood Coagulation and Thrombosis Mechanisms
- Advanced Breast Cancer Therapies
- Psoriasis: Treatment and Pathogenesis
- Colorectal Cancer Surgical Treatments
- Service-Learning and Community Engagement
- Advanced Proteomics Techniques and Applications
University of Copenhagen
2002-2018
University of Córdoba
2013
Rigshospitalet
1998-2012
Herlev Hospital
1985-2012
Erasmus MC
2012
Danish Breast Cancer Cooperative Group
2011
Hvidovre Hospital
1998-2009
Odense University Hospital
2009
Frederiksberg Hospital
2009
University of Oklahoma Health Sciences Center
2007
<h3>OBJECTIVE</h3> Urokinase type plasminogen activator (uPA) catalyses the formation of proteolytic enzyme plasmin, which is involved in matrix degradation processes tissue remodelling. Because a surface bound uPA receptor (uPAR), expressed by some cell types (for example, macrophages, malignant cells and inflammatory activated synoviocytes), action can be localised intensified. uPAR seems to have role mechanisms leading invasive growth rheumatoid pannus. may become cleaved at its anchor,...
Proliferative and anti-apoptotic actions of IGFs are mediated by the IGF-I receptor (IGF-IR), to which both -II bind with high affinity. We previously reported that αIGF-IR scFv-Fc (scFv-Fc) consisting scFv human IgG1 Fc domain retained general characteristics parental 1H7 monoclonal antibody, significantly suppressed MCF-7 tumor growth. proposed IGF-IR down-regulation as a possible mechanism for inhibition To further determine therapeutic potentials this approach, in vivo effects antibody...
A number of studies have demonstrated that high tumor tissue levels inhibitor metalloproteinases-1 (TIMP-1) are associated with a poor prognosis in breast cancer, suggesting TIMP-1 could be valid prognostic marker this disease. Recently, our laboratories presented results showing also carries information when measured serum. This is an important finding, since serum much more preferable material compared extracts. The aim the present study was to validate previous concerning value obtained...
Objective. Tissue inhibitor of metalloproteinases 1 (TIMP‐1) has been identified as a potential biomarker in diseases such cancer, cardiovascular and diabetes. Since TIMP‐1 resides most tissues bodily fluids, we evaluated the using saliva to obtain reproducible measurements non‐invasive manner. Material methods. Samples unstimulated stimulated whole collected from individual glands were analysed for content. A ELISA was validated use testing optimal sampling handling procedures identified....
Cloning and sequencing of the progesterone receptor gene in dogs have revealed 2 isoforms, A B, transcribed from a single gene. Distribution isoforms B canine mammary lesions has hitherto been investigated only by Western blot analysis. This study analyzed its formalin-fixed, paraffin-embedded tissue samples (4 dysplasias, 10 benign tumors, 46 carcinomas) using 1-step SYBR Green quantitative real-time polymerase chain reaction (RT-qPCR). Progesterone was expressed 75% all 59% carcinomas....
To assess the potential use of plasma and urine levels tissue inhibitor metalloproteinases 1 (TIMP-1) in urothelial cancer.TIMP-1 were determined from healthy donors (n=26), patients with bacterial bladder infection (n=24), adenoma (n=3) or adenocarcinoma (n=7).Free total TIMP-1 weakly but significantly correlated age; urinary was not. A strong correlation between free observed, an average ratio 0.85. No found (p=0.55). significant differences individuals, cystitis cancer (p=0.4). Urinary...
Early detection of colorectal cancer (CRC) improves patient survival. Plasma tissue inhibitor metalloproteinases 1 (TIMP-1) measurements by enzyme-linked immunosorbent assay (ELISA) have been suggested as a new method for the early CRC. To further investigate nature TIMP-1 in plasma, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF MS) was used. plasma from 16 healthy donors and 14 CRC patients were performed using monoclonal antibody SELDI MS ELISA....
Abstract Background: The topoisomerase-1 (TOP1) targeting drug irinotecan may be a new effective in the treatment of metastatic breast cancer patients1,2. However, use should guided by predictive biomarkers to avoid drug-induced site effects non-responding subgroup patients. A newly developed TOP1 fluorescence situ hybridization (FISH)3 probe mix (Dako, Denmark) represent such novel biomarker assay. Materials and Methods: TOP1/CEN-20 FISH was applied normal tissue (n = 100) human biopsy...
Abstract #6057 *Würtz SØ and Klintman M contributed equally, Malström P Brünner N shares the senior authorship.&#x2028; Background. Predictive markers are scarcely represented in breast cancer. TIMP-1 has a previous study (n = 173) performed our laboratory been shown to carry predictive information for response chemotherapy metastatic cancer as high tumor tissue levels of were significantly associated with low objective rate treatment most frequently used chemotherapeutic drugs (CMF...
Review of: PARADE: Celebrating Community in Action Washington Square Park, New York, 7 May 2023
Abstract Background: Topoisomerase 1 (TOP1) targeting drugs, e.g. irinotecan, are included in treatment regimens for different cancer types. Two clinical phase II studies1,2 suggested a role irinotecan the of metastatic breast patients being refractory to anthracyclines and taxanes. Access predictive biomarker would increase response rates secure that only with high likelihood obtaining benefit will receive drug. However, no biomarkers TOP1 drugs available. Experimental design: A TOP1/CEN-20...
597 Background: HER-2, TOP2A, and TIMP-1 have shown predictive properties regarding benefit from anthracyclines in patients with breast cancer. In the present study, IHC was integrated TOP2A FISH HER-2 status two separate profiles. Methods: The DBCG 89-D trial randomized 980 high-risk Danish cancer to nine series of CMF or CEF. CEF superior terms DFS OS (Ejlertsen et al, EJC 2007). copy number changes were determined as described previously (Knoop J Clin Oncol. 2005). TMA s constructed...
16014 Background: Patients (pts) with epithelial ovarian cancer (EOC) often relapse and rising CA 125 levels predate clinical or radiological appearance of tumor. High tumor serum urokinase plasminogen activator (uPA) in EOC correlate to adverse outcomes. Å6 is a novel peptide derived from human uPA that down-regulates the system has anti-angiogenic anti-metastatic activity animals. Methods: Pts EOC, fallopian tube, primary peritoneal remission after first line chemotherapy had have 2...
Introduction: There is a need for new and innovative solutions in the medical treatment of colon cancer since many these patients eventually develop resistance to currently used drugs leading untreatable disease death patients. We have by using our DEN50-R cell line based screening platform (isogenic pairs drug sensitive resistant human lines), followed testing PETACC-3 prospective randomized clinical study, identified ABCG2 TOP1 mRNA expression as significant predictive biomarkers...